Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07548879

Quantitative Analysis of Cardiac Muscle Perfusion

Full quantitative perfusion of the myocardial wall using MRI is a difficult method for several reasons. First the perfusion algorithm is mostly only relatively available, usually available algorithms /e.g. ISP/ shows not precise results according to our measurements, secondly based on signal physics and nature of MRI scans is not easy to get absolute numbers and specific new algorithms must be developed and tested. Such a tool is not only needed for some special cohort of patients, like 3-vessel disease, coronary artery disease or diffuse coronary artery involvement in coronary vasculopathy in patients after heart transplantation. Fully quantitative perfusion analysis is highly needed for nearly all cardiac patients to better characterise the health and status of the myocardium.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

St. Anne´s University Hospital Brno

Brno, 60200, Czechia

Location contact

Roman Panovský, MD

CONTACT

[email protected]

+420 543 18 2409

Roman Panovský, MD

PRINCIPAL_INVESTIGATOR

About this study

The aim of the study is to optimise the scanning and evaluation of stress perfusion with respect to the quantification of measurement results.

Cardiovascular diseases remain the leading cause of death among patients in developed countries. One of the most significant conditions within this group is ischemic heart disease (IHD), a state in which restricted blood flow through the coronary arteries results in myocardial ischemia.

At present, emphasis is placed on non-invasive diagnostic approaches to detect this condition. One such method is stress myocardial perfusion imaging.

Currently, this examination using magnetic resonance imaging (MRI) is mainly limited to qualitative assessment, in which the examiner evaluates perfusion defects based on a subjective visual assessment of myocardial blood flow, or semi-quantitative assessment, in which blood flow in individual myocardial segments is evaluated from the slope of signal-time curves. In this study, perfusion defects in individual segments will be assessed using quantitative analysis, i.e., direct calculation of blood flow in millilitres per gram of myocardial tissue, and the results will be compared with the aforementioned qualitative and semi-quantitative methods currently used in clinical practice.

In contrast, quantitative assessment of stress perfusion offers significant advantages, particularly the ability to provide an objective evaluation independent of the interpreting physician, improved diagnostic accuracy, and, importantly, the potential to diagnose patients with diffuse perfusion impairment across all vascular territories - for example, in those with three-vessel disease. However, fully quantified myocardial perfusion assessment is technically demanding and faces several limitations. The examination will be performed using a CE-marked Philips MRI system, with various frequencies and acquisition modules being evaluated.

The following quantitative CMR perfusion parameters will be analyzed:

Parameter Description Myocardial Blood Flow (MBF) Blood flow through the myocardium, expressed in ml/min/g of tissue. Measured for individual myocardial segments.

Myocardial Perfusion Reserve (MPR) Ratio of MBF during stress to MBF at rest: MPR = MBF_stress / MBF_rest, indicating the perfusion reserve.

Arterial Input Function (AIF) Contrast concentration in the left ventricle or aorta, serving as the reference input signal for MBF calculation.

Time to Peak (TTP) Time required for the myocardial signal to reach its maximum after bolus administration (indicator of delayed flow).

Upslope Slope of the rising phase of the perfusion curve - a relative measure of perfusion (often used in semi-quantitative analysis).

Peak Signal Intensity (PSI) Maximum signal value following contrast arrival (less commonly used as a standalone parameter).

Myocardial perfusion will be conducted according to the standard ESC perfusion protocol, using Gadolinium-based contrast agent (Gadovist) at a dose of 0.1 mmol/kg (0.1 ml/kg) administered at 3-5 ml/s, followed by 20 ml of saline flush. The contrast agent will be divided into two equal doses for stress and rest perfusion (0.05 ml/kg per perfusion). The stress agents used will be Adenosine (short-term infusion at 140 µg/kg/min using an infusion pump) or Regadenoson (400 µg intravenous bolus).

Patients with relative or absolute contraindications to stress testing will be excluded from the study, including those with acute coronary syndrome, life-threatening arrhythmias, severe COPD, second- or third-degree AV block, and patients with contraindications to MRI (ferromagnetic implants, severe renal failure, pregnancy).

The MRI protocol monitors contrast agent passage through the myocardium and subsequent washout for at least one minute in selected cardiac slices (typically three parallel short-axis slices from the apex to the base of the left ventricle). During the examination, basic physiological parameters are continuously monitored, including ECG, blood pressure, oxygen saturation (pO₂), and respiration. If necessary, the stress effect of the administered agent can be immediately reversed by administration of, for example, aminophylline. During scanning, changes in contrast concentration (signal intensity) are tracked over time. A targeted perfusion sequence (Philips DYNs_BTFE_3sl) will be used. For quantification purposes, this sequence will be complemented by a very short labeling sequence, which enables quantitative calculations while leaving the dynamic and pharmacological characteristics of the main perfusion sequence unaffected. After the examination, quantitative parameters from the perfusion sequence will be calculated to obtain the required perfusion metrics.

Analysis of the main perfusion parameters and other common cardiovascular metrics will be performed using Philips IntelliSpace Portal and CVI42 software.

The objective of the project is to optimize the scanning and evaluation process of stress perfusion MRI towards full quantification of measurement results, through collaboration between the clinical site and the MRI system manufacturer.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Signed informed consent
  • Patients indicated for a non-invasive test for ischemic heart disease/chronic coronary syndrome
  • Patients with intermittent chest pain and low to moderate probability of chronic coronary syndrome

Exclusion criteria

  • Presence of relative or absolute contraindications to stress testing, including acute coronary syndrome, life-threatening arrhythmias, severe chronic obstructive pulmonary disease (COPD), or second- or third-degree atrioventricular (AV) block.
  • Contraindications to MRI, such as severe claustrophobia, presence of ferromagnetic material or implants, or severe renal impairment.

Treatment and study plan

Magnetic Resonance Imaging with Contrast

Diagnostic Test

Myocardial perfusion will be conducted according to the standard ESC perfusion protocol, using Gadolinium-based contrast agent (Gadovist) at a dose of 0.1 mmol/kg (0.1 ml/kg) administered at 3-5 ml/s, followed by 20 ml of saline flush. The contrast agent will be divided into two equal doses for stress and rest perfusion (0.05 ml/kg per perfusion). The stress agents used will be Adenosine (short-term infusion at 140 µg/kg/min using an infusion pump) or Regadenoson (400 µg intravenous bolus).

Patients with relative or absolute contraindications to stress testing will be excluded from the study, including those with acute coronary syndrome, life-threatening arrhythmias, severe COPD, second- or third-degree AV block, and patients with contraindications to MRI (ferromagnetic implants, severe renal failure, pregnancy).

Primary outcomes

  1. The correlation between quantitative and semi-quantitative analyses

    Time frame: 1 day + up to 7 days after the examination

    The primary outcome measure is the degree of correlation between quantitative and semi-quantitative analyses of rest and stress myocardial perfusion assessed by magnetic resonance imaging (MRI), evaluated both globally and in individual myocardial segments.

Secondary outcomes

  1. Ratio between MBF during stress and rest

    Time frame: 1 day + up to 7 days after the indicated examination

    Degree of correlation between quantitative analysis parameters: Myocardial Blood Flow (MBF) in ml/min/g for each myocardial segment and Myocardial Perfusion Reserve (MPR) as ratio between MBF during stress and rest - MPR = MBF_stress / MBF_rest with already established semiquantitive parameters: Time to Peak (TTP) as time for the myocardial signal to reach peak after contrast bolus (indicator of low blood flow), Upslope as the slope of signal intensity increase in signal intensity to time curve of the myocardium and Peak Signal Intensity (PSI) as the maximal signal intensity reached after contrast agent bolus

  2. The predictive value of quantitative and semi-quantitative MRI perfusion

    Time frame: 1 day + up to 7 days after the indicated examination

    The secondary outcome measure is the predictive value of quantitative and semi-quantitative MRI perfusion results relative to findings from invasive coronary angiography and other functional stress tests.

Study contacts

Contact information is provided by the study sponsor or research team.

Roman Panovský, MD

CONTACT

[email protected]

+420 543 18 2409

Sponsors and collaborators

Lead sponsor

St. Anne's University Hospital Brno, Czech Republic

Other

Collaborators

  • Philips Medical Systems

Registry information

Acronym: KAPSS

Important dates

Study start
2026
Primary completion
2029
Study completion
2029
First posted
Apr 23, 2026
Registry last updated
Apr 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.